Navigation Links
Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Date:3/7/2012

s and kill prostate cancer cells across multiple genotypes in vitro and in vivo" (Abstract 1841; Section 30). 

Drs. Asfar Azmi and Ramzi Mohammed of Wayne State University will present two posters: "CRM-1 as a potential therapeutic target in pancreatic cancer" (Abstract 1815; Section 30) and "Novel small molecule CRM-1 inhibitor for Non Hodgkin's Lymphoma" (Abstract 1825; Section 30).

Drs. Roberto Fragomeni and James Cusack of Massachusetts General Hospital will present "Potent anticancer activity against both BRAF-mutant and BRAF wild-type melanoma cell lines using a novel CRM1 nuclear export inhibitor" (Abstract 1914; Section 34).

Drs. Christopher Walker and Danilo Perrotti of the Ohio State University will present "Nuclear export (karyopherin) inhibitors: A novel therapeutic strategy for treating Philadelphia-positive (Ph+) acute leukemias" (Abstract 3839; Section 32).

Dr. Dilara McCauley of Karyopharm will present "Selective inhibitors of nuclear export (SINE) induce multiple tumor suppressor proteins (TSP) activity and show single agent antitumor effect and synergy with Bcl-2 antagonist in non-small cell lung cancer" (Abstract 1831; Section 30).

Dr. Yosef Landesman of Karyopharm will present a poster, "Pharmacokinetic (PK) / pharmacodynamic (PDn) and efficacy relationship of selective inhibitors of nuclear export (KPT-SINE)" (Abstract 3775; Section 30).

Karyopharm's founder and Chief Scientific Officer Dr. Sharon Shacham commented, "We are very pleased to share the results of our continuing collaborative and internal work on the mechanisms of action and anti-tumor activity of SINE compounds in the treatment of a variety of malignant conditions. We are encouraged by their activity in dogs with naturally occurring and chemotherapy refractory tumors, and we are on track to bring our first in class, oral clinical candidate into Phase 1 studies this year."

About Karyopharm

Karyopharm
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
2. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
3. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
4. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
5. Orexigen Therapeutics to Present at Upcoming Conferences
6. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
10. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Delcath Systems, Inc. (NASDAQ: DCTH ... focused on oncology with an emphasis on the ... that results of a large, European single-center experience ... hepatic metastases with the Delcath Hepatic CHEMOSAT ® ... abstract at the American Society of Clinical Oncology ...
(Date:5/29/2015)... , May 29, 2015  Caris Life Sciences ... fulfilling the promise of precision medicine, today announced ... demonstrate the clinical utility of Caris Molecular Intelligence ... service, in helping to identify targeted treatment options ... each of the studies, results of which are ...
(Date:5/29/2015)... Results from a Phase III clinical ... ability to reduce the size of melanoma tumors in ... the Journal of Clinical Oncology. , The global, ... and IV melanoma, a potentially fatal form of skin ... evaluate the safety and efficacy of the oncolytic virus ...
(Date:5/28/2015)... DUBLIN , May 28, 2015 /PRNewswire/ ... ) has announced the addition of Jain ... Drugs, Markets and Companies"  to their offering.  ... ,Alzheimer,s disease remains a challenge in management. ... condition in the seven major markets of ...
Breaking Biology Technology:Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 2Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 4Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... , , , , , , , ... Protocol No. 4308 915.522 03/2002 , , , , , ... , Microorganism , Mycobacterium smegmatis LR222, ... Bacteria, gram positive, , , ...
... , , , , , , , , ... Protocol No. 4308 915.521 02/2002 , , , , , ... , Microorganism , Mycobacterium intracellulare 1403, ... Bacteria, gram positive, , , ...
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.520 12/2001 , ... , , , , ... , Cell type , Bacteria, gram ...
Cached Biology Technology:Mycobacterium smegmatis 2Mycobacterium intracellulare 2Listeria monocytogenes 2
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... the catalytic converter, an emissions control device in the ... But catalysts are used for a broad variety of ... into fuel, as well as the production of plastics, ... of the gross domestic product in the United States ...
... uses wireless sensors to track the vital signs of at-risk ... St. Louis. When the full system is operational sensors ... once or twice a minute. The data will be transmitted ... other data in the patient,s electronic medical record, such as ...
... Zoo was awarded two significant, highly competitive national grants ... American Association of Museums (AAM) and the U.S. ... support science education locally and abroad. "Science ... these grants will provide the assets necessary to deliver ...
Cached Biology News:University of Virginia researchers uncover new catalysis site 2Wireless network in hospital monitors vital signs 2Wireless network in hospital monitors vital signs 3Wireless network in hospital monitors vital signs 4Wireless network in hospital monitors vital signs 5Wireless network in hospital monitors vital signs 6Lincoln Park Zoo awarded 2 significant grants for science education 2Lincoln Park Zoo awarded 2 significant grants for science education 3
... plasmid DNA preparations are prepared from ... from 1mg to multi-gram scales. ... (100mg-multi-gram) preparations are made according to ... formulated according to customer needs, and ...
... Digital Clamp One can operate as a ... a Conductance (Dynamic) Clamp in electrophysiology research applications. ... good as conventional analog equipment. This amazing ... in the capabilities of Digital Signal Processing (DSP) ...
... Display Cloning System facilitates the display of ... bacteriophage M13 as coat protein fusions, creating ... and its encoding DNA sequence. Peptide ligands ... be selected by the straightforward method of ...
... key to successful cell culture or fermentation ... during the process, and make rapid adjustments ... Nova BioProfile Chemistry Analyzers provide immediate analysis ... cell culture and fermentation media. BioProfile analyzers ...
Biology Products: